<DOC>
	<DOCNO>NCT02856997</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Chidamide ICE regimen patient relapsed/refractory Peripheral T Cell lymphoma .</brief_summary>
	<brief_title>Chidamide With ICE Regimen Relapsed/Refractory Peripheral T Cell Lymphoma</brief_title>
	<detailed_description>Efficacy combine regimen evaluate primarily objective remission rate , include complete remission , unverified complete remission partial remission , also duration remission , progression free survival , overall survival . Safety access : 1 . The type , incidence , severity incident relate use regimen . 2 . Laboratory abnormality , include type , incidence , severity , relationship use regimen . 3 . Incidence level 3-4 incident laboratory abnormality .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Patients Peripheral T Cell Lymphoma ( PTCL ) verify histopathology/ cytology , accord WHO 2008 classification criterion , include : adult T cell lymphoma leukemia ( human T cell leukemia virus 1 positive ) ; angioimmunoblastic cell lymphoma ; ALK positive anaplastic large cell lymphoma ; ALK negative anaplastic large cell lymphoma ; nonspecified peripheral T cell lymphoma ; extranodal NK/T cell lymphoma ; bowl disease related T cell lymphoma ; hepatosplenic T cell lymphoma ; subcutaneous panniculitislike T cell lymphoma ; allergic mycosis fungoides . 2 . There least 1 focus could evaluate histopathology cytology ( ˃1.5cm ) accord Cheson criterion . 3 . The patient least 1 course systemic treatment ( include chemotherapy , stem cell transplantation etc ) , achieve remission relapse remission . 4 . Age1875 year , male female ; 5 . General condition ECOG 01 . 6 . Blood routine test : absolute neutrophil count ≥1.5 × 109/L , platelet ≥80 × 109/L , Hb ≥ 90g/L ; 7 . Expected survival ≥ 3 month ; 8 . No radiotherapy , chemotherapy , target therapy hemopoietic stem cell transplantation receive within 4 week prior enrollment . 9 . Willing sign write consent . 1 . Women pregnancy lactation , fertile woman unwilling take contraceptive measure . 2 . QTc elongation clinical significance ( male˃ 450ms , female˃ 470ms ) , ventricular tachycardia , atrial fibrillation , cardiac conducting blockage , myocardial infarction within 1 year , congestive heart failure , symptomatic coronary heart disease require treatment . 3 . Patients receive organ transplantation . 4 . Patients receive symptomatic treatment bone marrow toxicity within 7 day prior enrollment . 5 . Patients active hemorrhage . 6 . Patients history thrombosis , embolism , cerebral hemorrhage , cerebral infarction . 7 . Patients active infection , continuous fever within 14 day prior enrollment . 8 . Had major organ surgery within 6 week prior enrollment . 9 . Impaired liver function ( Total bilirubin ˃ 1.5 time normal maximum , ALT/AST˃ 2.5 time normal maximum , patient infiltrative liver disease ALT/AST ˃ 5 time normal maximum ) , impaired renal function ( serum creatinin˃ 1.5 time normal maximum ) . 10 . Patients mental disorder ability consent . 11 . Patients drug abuse , long term alcoholism may impact result trial . 12 . Nonappropriate patient trial accord judgment investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>